Magnetically Actuated Iron Oxide Nanoparticles Sensitize Acute T-Lymphocyte Leukemia Cells to Vincristine via Reprogramming Cellular Homeostasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41968648.
- Also identified by DOI 10.1021/acs.nanolett.6c01231.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vincristine (VCR) is a first-line chemotherapeutic agent for pediatric T-cell acute lymphoblastic leukemia (T-ALL), while its clinical efficacy is limited by dose-dependent peripheral neurotoxicity. As T cells in normal physiological environments experience various mechanical forces and VCR targets a mechanosensitive cellular microtubule, in this study, we developed a magnetically actuated mechanical stimulation (MAMS) strategy utilizing superparamagnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles (IONPs) and an external static magnetic field (MF), which combined with VCR to significantly enhance the chemosensitivity of T-ALL cells. It was demonstrated that the IONPs primarily bound to the membrane of Jurkat cells and formed ordered assembly structures under MF, which disrupted cellular homeostasis by activating the calcium-NFAT-FasL signaling pathway, hyperpolarizing mitochondria, reprogramming metabolism, and disrupting cytoskeletal assembly. In conclusion, the MAMS strategy sensitized Jurkat cells to VCR by multilevel interference with the homeostasis of cells, providing a promising approach for developing more effective and less cytotoxic T-ALL treatment regimens.
Medical subject headings
- Vincristine
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Magnetic Iron Oxide Nanoparticles
- Antineoplastic Agents, Phytogenic